Please wait while the transcript is being prepared...
0:00
Welcome to this
lecture on CAR-T,
chimeric antigen
receptor T-cell therapy,
providing an overview of
the fundamentals of
CAR-T cell therapy,
including how a
patient's T-cells
are engineered to target
cancer and the step by
step process from cell
collection to infusion.
We will discuss the successes
of CAR-T in treating
certain blood cancers and
its impact on
hematologic oncology.
Key challenges such as
treatment-related toxicities
and manufacturing hurdles
will be addressed.
Lastly, we will explore
ongoing research aimed at
expanding CAR-T applications and
improving its safety
and effectiveness.
We will explore
CAR-T cell therapy,
a revolutionary
approach in treating
certain cancers using the
body's own immune system.
CAR-T stands for chimeric
antigen receptor
T-cell therapy which
involves engineering
a patient's T-cells
to express a synthetic receptor,
the CAR, designed to recognize
antigens on cancer cells.
This enables T-cells to target
and attack tumor cells directly,
empowering the immune system to
destroy previously
elusive cancer cells.
The CAR-T cell journey
begins with leukapheresis,
where T-cells are collected
from the patient's blood.
In the lab, these
cells are genetically
modified often
with viral vectors
to introduce the CAR construct.
The engineered T-cells are
expanded before being infused
back into the patient.
Once inside, CAR-T cells
seek out cells
displaying the target
antigen such as CD19 in
B cell malignancies.
